ArticleIJU case reports2020
Undifferentiated prostate cancer treated with docetaxel.
Article in IJU case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Undifferentiated prostate cancer treated with docetaxel.IJU case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUndifferentiated prostate cancer is a rare and aggressive disease, and no definitive therapeutic strategy for metastatic undifferentiated prostate cancer has been established. CASE PRESENTATION: We report the case of a 70-year-old man with undifferentiated prostate cancer and lymph node metastases. Following the patient's progression after platinum-based chemotherapy, we initiated treatment with docetaxel, which resulted in a partial response. The patient was alive for 42 months after initiation of docetaxel, maintaining relatively good quality of life with minimal hospital stay.
conclusionDocetaxel may be a good therapeutic option for metastatic undifferentiated prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.